US Stock MarketDetailed Quotes
RSLS ReShape Lifesciences
- 4.3800
- -0.0900-2.01%
Close Dec 20 16:00 ET
- 4.3800
- 0.00000.00%
Post 20:01 ET
3.12MMarket Cap-0.44P/E (TTM)
4.6900High4.2754Low41.47KVolume4.3800Open4.4700Pre Close185.60KTurnover6.14%Turnover RatioLossP/E (Static)712.68KShares29.000052wk High2.10P/B2.96MFloat Cap4.090052wk Low--Dividend TTM675.25KShs Float4647888000.0000Historical High--Div YieldTTM9.28%Amplitude4.0900Historical Low4.4750Avg Price1Lot Size
ReShape Lifesciences Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 88.81%-311K | 79.63%-1.36M | 59.06%-2.07M | 22.56%-16.96M | 13.15%-2.46M | 47.28%-2.78M | -3.74%-6.66M | 31.40%-5.06M | -42.45%-21.9M | 17.43%-2.83M |
| Net income from continuing operations | 55.26%-1.58M | 54.34%-1.6M | 17.62%-2.19M | 75.36%-11.39M | 89.69%-1.7M | 71.00%-3.53M | 63.01%-3.49M | 67.20%-2.66M | 26.81%-46.21M | 55.09%-16.47M |
| Operating gains losses | 93.20%-28K | 15.81%-426K | 99.29%-21K | -839.32%-3.91M | -119.18%-28K | -20,700.00%-412K | ---506K | ---2.97M | -89.15%529K | --146K |
| Depreciation and amortization | -90.00%5K | -87.76%6K | -87.50%6K | -92.85%154K | -98.64%7K | -90.79%50K | -91.01%49K | -91.27%48K | 9.23%2.15M | -7.21%515K |
| Deferred tax | -150.00%-1K | --0 | 200.00%1K | 106.62%28K | 149.09%27K | 100.54%2K | --0 | ---1K | -70.56%-423K | 77.82%-55K |
| Other non cash items | --0 | -88.89%1K | -99.67%1K | 173.91%17K | -14,550.00%-293K | --0 | 350.00%9K | 1,605.00%301K | -103.67%-23K | -111.76%-2K |
| Change In working capital | 560.09%1M | 108.30%258K | 1,065.96%454K | -683.07%-4.13M | -174.53%-761K | 80.16%-218K | -321.53%-3.11M | 92.37%-47K | 126.14%709K | 197.67%1.02M |
| -Change in receivables | 60.37%-191K | -82.05%7K | 1,995.24%440K | -81.56%125K | 2,504.76%547K | -359.14%-482K | -57.61%39K | -94.46%21K | 338.73%678K | -96.59%21K |
| -Change in inventory | 812.90%283K | -61.90%64K | 196.30%320K | 60.83%-465K | -693.85%-772K | -11.43%31K | 160.22%168K | 110.07%108K | -221.68%-1.19M | 133.33%130K |
| -Change in prepaid assets | -37.59%88K | 174.29%78K | 87.12%-47K | -115.07%-172K | -64.72%157K | -58.89%141K | -121.43%-105K | -166.42%-365K | 1,601.32%1.14M | 37.77%445K |
| -Change in payables and accrued expense | 1,092.75%823K | 103.43%109K | -175.29%-259K | -871.65%-3.46M | -238.88%-693K | 104.45%69K | -352.14%-3.18M | 43.33%344K | 135.00%448K | -10.57%499K |
| -Change in other current liabilities | --0 | --0 | --0 | 50.94%-182K | --0 | 95.54%-5K | 79.38%-33K | -476.00%-144K | 47.23%-371K | 79.21%-74K |
| -Change in other working capital | ---- | ---- | ---- | --17K | --0 | --28K | --0 | ---11K | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 88.81%-311K | 79.63%-1.36M | 59.06%-2.07M | 22.56%-16.96M | 13.15%-2.46M | 47.28%-2.78M | -3.74%-6.66M | 31.40%-5.06M | -42.45%-21.9M | 17.43%-2.83M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | 0 | 0 | 89.13%-10K | 0 | 0 | -116.67%-3K | -450.00%-7K | -104.96%-92K | 97.42%-79K |
| Capital expenditure reported | --0 | --0 | --0 | 67.18%-43K | --0 | --0 | -200.00%-36K | 0.00%-7K | 62.78%-131K | -17.91%-79K |
| Net PPE purchase and sale | --0 | ---- | ---- | -15.38%33K | --0 | --0 | ---- | ---- | --39K | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | --0 | --0 | 89.13%-10K | --0 | --0 | -116.67%-3K | -450.00%-7K | -104.96%-92K | 97.42%-79K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 0 | -98.93%24K | 0 | 461.47%17.57M | 755.96%5.46M | -11,366.67%-338K | -9.60%2.25M | 10.2M | -90.60%3.13M | 638K |
| Net common stock issuance | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --10.2M | ---- | ---- |
| Proceeds from stock option exercised by employees | --0 | ---- | ---- | 66.04%4.14M | 413,700.00%4.14M | -415,133.33%-12.45M | ---- | ---- | -94.59%2.49M | ---1K |
| Net other financing activities | ---- | ---- | ---- | 2,002.97%13.44M | --13.78M | ---- | ---- | ---- | 119.76%639K | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | --0 | -98.93%24K | --0 | 461.47%17.57M | 755.96%5.46M | -11,366.67%-338K | -9.60%2.25M | --10.2M | -90.60%3.13M | --638K |
| Net cash flow | ||||||||||
| Beginning cash position | -75.29%1.15M | -72.71%2.48M | 15.27%4.56M | -82.66%3.96M | -75.20%1.55M | -59.57%4.67M | -41.25%9.08M | -82.66%3.96M | 658.73%22.82M | -78.68%6.25M |
| Current changes in cash | 90.03%-311K | 69.81%-1.33M | -140.37%-2.07M | 103.20%604K | 232.33%3M | 41.20%-3.12M | -12.77%-4.42M | 169.59%5.13M | -195.37%-18.86M | 65.04%-2.27M |
| Effect of exchange rate changes | --1K | 800.00%7K | -60.00%-8K | --0 | 130.00%6K | --0 | 0.00%-1K | -123.81%-5K | -86.21%4K | -233.33%-20K |
| End cash Position | -45.58%843K | -75.29%1.15M | -72.71%2.48M | 15.27%4.56M | 15.27%4.56M | -75.20%1.55M | -59.57%4.67M | -41.25%9.08M | -82.66%3.96M | -82.66%3.96M |
| Free cash flow | 88.81%-311K | 79.74%-1.36M | 59.12%-2.07M | 22.83%-17M | 15.51%-2.46M | 47.61%-2.78M | -4.10%-6.7M | 31.37%-5.07M | -40.10%-22.03M | 16.75%-2.91M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- |
Heat List
US
Overall
Symbol
Price
% Chg
No Data